Cargando…
When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973077/ https://www.ncbi.nlm.nih.gov/pubmed/33810939 http://dx.doi.org/10.1016/j.ejim.2021.03.016 |
| _version_ | 1783666771061899264 |
|---|---|
| author | Dal-Ré, Rafael Banzi, Rita |
| author_facet | Dal-Ré, Rafael Banzi, Rita |
| author_sort | Dal-Ré, Rafael |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7973077 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Federation of Internal Medicine. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79730772021-03-19 When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine Dal-Ré, Rafael Banzi, Rita Eur J Intern Med Commentary European Federation of Internal Medicine. Published by Elsevier B.V. 2021-05 2021-03-19 /pmc/articles/PMC7973077/ /pubmed/33810939 http://dx.doi.org/10.1016/j.ejim.2021.03.016 Text en © 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Dal-Ré, Rafael Banzi, Rita When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine |
| title | When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine |
| title_full | When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine |
| title_fullStr | When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine |
| title_full_unstemmed | When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine |
| title_short | When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine |
| title_sort | when is it reasonable to extrapolate during a pandemic?: the case of broad uk labeling for astrazeneca covid-19 vaccine |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973077/ https://www.ncbi.nlm.nih.gov/pubmed/33810939 http://dx.doi.org/10.1016/j.ejim.2021.03.016 |
| work_keys_str_mv | AT dalrerafael whenisitreasonabletoextrapolateduringapandemicthecaseofbroaduklabelingforastrazenecacovid19vaccine AT banzirita whenisitreasonabletoextrapolateduringapandemicthecaseofbroaduklabelingforastrazenecacovid19vaccine |